VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma. - Wikidata - awgldk - TriplyDB

VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma.

VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma.

http://www.wikidata.org/entity/Q37619546

about

VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma.

http://www.wikidata.org/entity/Q37619546

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

VIP (etoposide, ifosfamide, an ...... y treated soft tissue sarcoma.

@en

VIP (etoposide, ifosfamide, an ...... y treated soft tissue sarcoma.

@nl

type

label

VIP (etoposide, ifosfamide, an ...... y treated soft tissue sarcoma.

@en

VIP (etoposide, ifosfamide, an ...... y treated soft tissue sarcoma.

@nl

prefLabel

VIP (etoposide, ifosfamide, an ...... y treated soft tissue sarcoma.

@en

VIP (etoposide, ifosfamide, an ...... y treated soft tissue sarcoma.

@nl

P1433

Q37619546-0B5D6D6B-44E0-4E30-90FC-AA89A8C57059

P1476

Q37619546-67076CD8-54BA-43FF-A22E-A1758D114A20

P2093

Q37619546-229C6A5A-CE44-4F5C-9712-39A0BEF8EE30

Q37619546-2C18401F-E5DA-43C9-9133-A9AC18F71C94

Q37619546-57A4D517-04D2-4796-A2D8-A0E917492A4F

Q37619546-693E91E1-4DDC-4B6E-954A-2AE8B2537A07

Q37619546-7FEBF14B-E508-4E97-A376-BFB565A81DF5

Q37619546-814BA68E-E0B0-4F4B-AC43-0CC05AAFD91F

Q37619546-CEF625C7-A714-49E8-941B-D7A2EAA683D2

P2860

Q37619546-0D05B026-01C3-4642-8202-43F034C363C4

Q37619546-14433C6C-41B2-44A2-B4A3-478DD0CBE494

Q37619546-16515ED1-9A82-49ED-B7E2-DFF8247CE32F

Q37619546-228C05EC-5834-45E8-910F-E86FF2D34050

Q37619546-280CC914-DC2B-4B1C-81A8-893C8BB40942

Q37619546-339CD64B-F36A-4F21-930D-DE2232FAA2B6

Q37619546-37703FE9-05D6-4095-8323-B6F8D34C3C0E

Q37619546-428095C7-3001-4F30-8D21-F8CB0E783749

Q37619546-44763B3F-760D-4F52-9493-BACB52C2A8C2

Q37619546-4DD8E066-A11D-41E2-952B-BB1D7FEC9BED

P304

Q37619546-1393412E-3E31-4718-BD91-7E14E7E22912

P31

Q37619546-9E1B31EC-4090-4296-BD03-4492AE3D3A92

P356

Q37619546-3BA4429F-C158-4381-AA7F-DC03F9D28992

P407

Q37619546-B238B042-B8D4-4ECF-BFA6-9F23DED703EC

P433

Q37619546-C6044895-4B84-449F-B82C-D0B52384E02B

P478

Q37619546-2DD2BCA3-AAE9-41BA-883A-427189B0D75A

P50

Q37619546-8885A07D-84D5-4795-8C80-411D319625E6

Q37619546-BCC893F3-21FF-4A68-9850-2599FBFF8A0D

P577

Q37619546-ABB43DF3-F8E7-45CC-9389-F1D875581891

P698

Q37619546-252981D9-768C-439C-B005-993C80B3D1AB

P932

Q37619546-AFB61431-F377-4D6D-A105-0E9BA8DA92AD

P356

MD.0000000000005942

P1433

P1476

VIP (etoposide, ifosfamide, an ...... ly treated soft tissue sarcoma

@en

P2093

Deog-Yeon Jo

http://www.w3.org/2001/XMLSchema#string

Hyewon Ryu

http://www.w3.org/2001/XMLSchema#string

Ik-Chan Song

http://www.w3.org/2001/XMLSchema#string

Ji Young Moon

http://www.w3.org/2001/XMLSchema#string

Samyong Kim

http://www.w3.org/2001/XMLSchema#string

Seung-Woo Baek

http://www.w3.org/2001/XMLSchema#string

Yoon-Seok Choi

http://www.w3.org/2001/XMLSchema#string

P2860

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.

Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group.

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma.

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

P304

e5942

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MD.0000000000005942

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28121937

http://www.w3.org/2001/XMLSchema#string

P932

5287961

http://www.w3.org/2001/XMLSchema#string